Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, …
4 days ago · The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The …
FDA expands approval of Moderna's RSV vaccine to some adults …
2 days ago · The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at …
mRESVIA® (Respiratory Syncytial Virus Vaccine) I Official US ... - Moderna
mRESVIA is a vaccine indicated for the prevention of lower respiratory tract disease and acute respiratory disease caused by respiratory syncytial virus (RSV) in adults aged 60 or older.
Moderna’s mRNA RSV vaccine wins expanded FDA approval for …
2 days ago · Moderna’s vaccine, known under the brand name mRESVIA, became the first non-Covid-19 messenger RNA-based (mRNA) vaccine to be approved in the US in May 2024. …
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA …
3 days ago · CAMBRIDGE, MA/ ACCESS Newswire/ June 12, 2025/ Moderna, Inc. today announced that the U.S. Food and Drug Administration has approved mRESVIA ®, the …
Moderna RSV Vaccine Summary | Vaccines & Immunizations
Jul 5, 2024 · mRESVIA is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. When ordering vaccines directly from Moderna, …
US FDA Approves Expanded Use of Moderna's RSV Vaccine for …
3 days ago · Moderna's RSV shot, mRESVIA, was the first non-COVID-19 messenger RNA-based (mRNA) vaccine to be approved in the United States. The shot, the company's second …
mRESVIA® (Respiratory Syncytial Virus Vaccine) - Moderna
Online: Moderna's Adverse Event Intake Portal or U.S. HHS's Vaccine Adverse Event Reporting System. Email:[email protected] Call:1-866-MODERNA (1-866-663-3762) Monday - …
FDA expands approval for Moderna's RSV vaccine | KXAN Austin
9 hours ago · The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for …
MRESVIA | FDA - U.S. Food and Drug Administration
Dec 26, 2024 · Rolling BLA (Part 1 of 2) - Active immunization for the prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory …
- Some results have been removed